TNFRSF18 and neoplasm: In contrast, a combination ofanti-PD-1/GITR mAb with cisplatin or paclitaxel significantly suppressed tumor growthand 80% of mice (4 mice out of 5) survived tumor-free when the experiment wasterminated 90 days after tumor challenge.